Most people recover completely from viral hepatitis B, but
the infection may incapacitate a person for weeks or months during the
acute phase.
The risk of chronicity is higher for infected children, with up to 90
percent of newborns and 50 percent of pre-schoolers becoming chronic carriers.
The likelihood of transmission from mother to newborn depends on the level
of hepatitis B virus in the mother's blood; up to 90% of newborns born
to highly infected mothers are themselves infected and become chronic
carriers.
Such protection is available through a safe and effective vaccine that
provides immunity to hepatitis B infection.
Verena Muzio
conf pdf/Verena Muzio.pdf Despite advances in antiviral therapies, there is no effective
treatment for hepatitis B infection.
Thus, primary prevention by vaccination remains the main strategy to control
hepatitis B virus infection.
Heberbiovac HB, the Cuban recombinant yeast derived hepatitis B vaccine,
has been widely use in Cuba and worldwide.
Additionally, looking for new alternatives in hepatitis B vaccination,
novel vaccine candidates by intranasal administration route are currently
under study at CIGB.
Preliminary results in mice indicated that the nasal route, besides the
induction of a potent mucosal immunity, could be as efficient as the systemic
route in the induction of strong and long-term antibody responses in sera.
ehas_hepatitis-vacine-recall
A unit of the French pharmaceutical group, Aventis, which sells
the vaccine in Europe in a joint venture with Merck, disclosed in December
that it was recalling batches of pre-filled syringes because they might
not be potent enough to protect against the virus, which is spread by
poor sanitation and can cause liver damage.
Merck commented on the potential number of people affected by the faulty
vaccine in response to inquiries by Reuters following reports by local
newspapers in Brazil about the use of the possibly ineffective vaccine
in Brazil.
He added that the Brazilian clinics that gave the vaccine are contacting
patients so that they can return for testing and perhaps a new shot.
The hepatitis C virus (HCV) is one of the most important causes
of chronic liver disease in the United States.
At least 75 percent of patients with acute hepatitis C ultimately develop
chronic infection, and most of these patients have accompanying chronic
liver disease.
Testing for HCV RNA (by PCR) confirms the diagnosis and documents that
viremia is present; almost all patients with chronic infection will have
the viral genome detectable in serum by PCR.
In the United States, two different regimens have been approved as therapy
for hepatitis C: Monotherapy with alpha interferon Combination therapy
with alpha interferon and ribavirin.
Fshepb
Most people who get the disease recover from it and can never
get it again.
Hepatitis B virus (HBV) is spread by contact with the blood, semen, vaginal
fluids, or certain other body fluids of an infected person.
When these fluids enter a person's blood through mucous membranes (such
as those in the mouth or organs) or breaks in the skin, the virus
can also enter.
About one of every three hepatitis B cases in the U.S. does not know where
they got their infection.
People who have not had the vaccine and become exposed to the virus should
get a shot called HBIG, as well as the vaccine.
He_JGV_84
HCV polyprotein translation is initiated by an internal ribosome-entry
site (IRES) located at the 5 9 end of the viral genome, in a cap-independent
manner, but the regulatory mechanism of this process remains poorly understood.
In this study, we characterized the effect of HCV nonstructural proteins
on HCV IRES-directed translation in both HCV replicon cells and transiently
transfected human liver cells expressing HCV nonstructural proteins.
HCV replicon cells show decreased levels of eIF2a and eIF4E phosphorylation
Our previous study (He et al., 2001) showed that NS5A was able to decrease
the phosphorylation levels of both eIF2 a and eIF4E, suggesting a possible
mechanism by which HCV may differentially regulate cap-dependent and -independent
translation initiation.
color_cs1
Legend: Public Health Image Library, CDC, public domain.
Occupational indications: health-care workers and publicsafety workers
who have exposure to blood in the workplace, persons in training in schools
of medicine, dentistry, nursing, laboratory technology, and other allied
health professions.
Hepatitis A series This schedule indicates the recommended ages for routine
administration of currently licensed childhood vaccines, as of December
1, 2002, for children through age 18 years.
All infants should receive the first dose of hepatitis B vaccine soon
after birth and before hospital discharge; the first dose may also be
given by age 2 months if the infant's mother is HBsAg-negative.
012
The guidelines have been developed to provide the ordering
physician with a clear and concise reference describing appropriate testing
and reporting algorithms for the diagnosis of infection, exposure and
immunization.
Infection in young adults leads to chronicity in 5% of cases but, infection
in older adults is associated with increased rates of chronicity.
If knowledge of the immune status to Hepatitis A or B is required, the
laboratory will test for anti-HAV IgG or total anti-HAV or for anti-HBs,
as requested.
The OAML gratefully acknowledges the contributions of the members of the
Guideline Panel and others who have contributed their expertise, advice
and technical support to the development and review of this guideline.
CME_HCV_Journal_Article_1567
http://www.labcorp.com/cme/pdf/CME_HCV_Journal_Article_1567.pdf 2. Identify the risk factors for hepatitis C virus infection.
Unlike HBV, there are no vaccines for hepatitis C virus (HCV), which has
a significantly high rate of morbidity and mortality.
The development of vaccines is thwarted by great heterogeneity of the
HCV genome.11 More research is needed to solve this problem.
The National Genetics Institute's qualitative HCV PCR assay (UltraQualTM)
is the first assay approved for plasma donor screening.
has been determined from various studies that the United States has approximately
70 percent genotype 1, approximately 16 percent genotype 2, 13 percent
genotype 3, and less than 1 percent other genotypes.10 There are several
reliable methods for determining HCV genotype.11 The most commonly used
methods are direct DNA sequencing and hybridization.
18642ft
http://www.socgenmicrobiol.org.uk/JGVDirect/18642/18642ft.pdf A molecular analysis of partial sequences in the E1 (envelope)
and NS5-B (polymerase) genes was performed.
Phylogenetic reconstruction showed that the evolution of dominant strains
was qualitatively and quantitatively different in BDs and BRs.
During the second half of the twentieth century, several million persons
have been contaminated by hepatitis C virus (HCV) following blood transfusion.
Taken together, these different findings can be used to sharpen the analysis
of the long-term evolution of HCV.
First, evolution is certainly dependent on the mode of virus transmission
and the titre of inoculum.
Second, it appears that a large part of virus evolution is acquired during
the early stages of infection.
Hepatitis
The guidelines also ask laboratories to automatically perform
reflex testing in certain situations.
Although ARUP supports S/CO reporting, ARUP will not be automatically
performing reflex testing because of compliance issues.
Chronic infection is responsible for an estimated 8,000 to 10,000 deaths
per year.
The antibody tests include enzyme immunoassays (EIAs) and a chemiluminescent
immunoassay (CIA), which detect antibodies to HCV (anti-HCV), and a supplemental
recombinant immunoblot assay (RIBA), which detects the pattern of antibodies.
ARUP Laboratories uses the VITROS® ECi anti-HCV chemiluminescent
immunometric assay (CIA) as a screening test for HCV IgG antibody (anti-HCV).
If reporting anti-HCV results in S/CO values, the CDC recommends that
laboratories reflexively perform a RIBA test on all low positive screens.
